Skip to main content
Erschienen in: BMC Cancer 1/2023

Open Access 01.12.2023 | Research

Abdominal fat and muscle distributions in different stages of colorectal cancer

verfasst von: Jun Han, Xinyang Liu, Min Tang, Fan Yang, Zuoyou Ding, Guohao Wu

Erschienen in: BMC Cancer | Ausgabe 1/2023

Abstract

Background

The purpose of this study is to explore the difference of abdominal fat and muscle composition, especially subcutaneous and visceral adipose tissue, in different stages of colorectal cancer (CRC).

Materials and methods

Patients were divided into 4 groups: healthy controls (patients without colorectal polyp), polyp group (patients with colorectal polyp), cancer group (CRC patients without cachexia), and cachexia group (CRC patients with cachexia). Skeletal muscle (SM), subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and intermuscular adipose tissue (IMAT) were assessed at the third lumbar level on computed tomography images obtained within 30 days before colonoscopy or surgery. One-way ANOVA and linear regression were used to analyze the difference of abdominal fat and muscle composition in different stages of CRC.

Results

A total of 1513 patients were divided into healthy controls, polyp group, cancer group, and cachexia group, respectively. In the development of CRC from normal mucosa to polyp and cancer, the VAT area of the polyp group was significantly higher than that of the healthy controls both in male (156.32 ± 69.71 cm2 vs. 141.97 ± 79.40 cm2, P = 0.014) and female patients (108.69 ± 53.95 cm2 vs. 96.28 ± 46.70 cm2, P = 0.044). However, no significant differences were observed of SAT area between polyp group and healthy controls in both sexes. SAT area decreased significantly in the male cancer group compared with the polyp group (111.16 ± 46.98 cm2 vs. 126.40 ± 43.52 cm2, P = 0.001), while no such change was observed in female patients. When compared with healthy controls, the SM, IMAT, SAT, and VAT areas of cachexia group was significantly decreased by 9.25 cm2 (95% CI: 5.39–13.11 cm2, P < 0.001), 1.93 cm2 (95% CI: 0.54–3.32 cm2, P = 0.001), 28.84 cm2 (95% CI: 17.84–39.83 cm2, P < 0.001), and 31.31 cm2 (95% CI: 18.12–44.51 cm2, P < 0.001) after adjusting for age and gender.

Conclusion

Abdominal fat and muscle composition, especially SAT and VAT, was differently distributed in different stages of CRC. It is necessary to pay attention to the different roles of subcutaneous and visceral adipose tissue in the development of CRC.
Begleitmaterial
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1186/​s12885-023-10736-2.
Jun Han, Xinyang Liu and Min Tang contributed equally to this work as co-first authors.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Colorectal cancer (CRC) remains a major health burden with high mortality throughout the world. Globally, there are 1.8 million cases and 880,792 deaths from CRC in 2018 [1]. With the changes in lifestyle such as the lack of physical activity, and the increasing prevalence of obesity in recent decades, the incidence of CRC in China has been raised [2]. It is well known that colorectal polyp is a key step in CRC development. Different polyp subtypes lead to cancer development through distinct neoplasia pathways, in which the adenoma-carcinoma pathway contributes up to 60–70% of all CRC [3]. A number of epidemiological studies have reported an association between the risk for CRC and obesity [4, 5]. Visceral obesity was reported as a risk factor for colorectal adenoma [6]. However, whether adipose tissue is increasing from adenoma to carcinoma is still unclear.
Human white adipose tissue is a prominent energy reservoir and can be categorized into subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) [7]. Recent studies have shown that the metabolic characteristics and embryonic origin of SAT and VAT are different [79]. Increased VAT is a risk factor for various tumors, including CRC [10, 11]. VAT is also associated with a higher incidence of colorectal adenoma in a dose-dependent manner [12]. On the other hand, the increase of SAT is not associated with CRC and is even negatively associated with CRC in African Americans [13]. In addition, the prognostic value of SAT and VAT is also different in various cancers [14, 15]. Intramuscular adipose tissue (IMAT) is a measure of adipose tissue infiltration in skeletal muscle fibers [16]. IMAT highly correlates with muscle density and can lead to a higher risk of adverse health outcomes [17, 18]. However, the role of IMAT in the development of CRC is unclear.
Measurement of waist circumference and body mass index (BMI) are two conventional methods to determine the abdominal fat and muscle composition. However, such methods cannot accurately distinguish SAT and VAT. In recent years, with the application of imaging techniques such as computed tomography (CT) scans, abdominal fat and muscle composition can be accurately segmented to be SAT and VAT as well as IMAT and skeletal muscle (SM) [19, 20]. The third lumbar vertebra (L3) is a common reference point for the estimation of abdominal fat and muscle composition [21, 22]. With its power to use neural networks and convolutional layers to learn the hierarchy of features from a large amount of given data, deep learning systems can be trained to analyze abdominal fat and muscle composition [23, 24]. In a previous study, we have developed a V-Net-Based segmentation deep learning system to segment skeletal muscle and adipose tissues quickly and accurately [15]. It provides a useful method for large-scale calculation of human abdominal fat and muscle composition (SM, SAT, VAT, and IMAT).
Cancer cachexia is a common phenomenon of advanced tumors, which is mainly characterized by loss of skeletal muscle and adipose tissues [25]. A large number of studies have shown that skeletal muscle atrophy is an independent prognostic factor of cancer patients with cachexia [2628]. However, prognostic value of adipose tissue loss in patients with cancer cachexia is still controversial [15, 29, 30]. Given CRC often occurs in obese patients, it is not clear whether CRC patients with cachexia would experience adipose tissue loss as other cancer patients do.
In this study, we compared the abdominal fat and muscle composition differences in different stages of colorectal cancer (patients with and without colorectal polyp, CRC patients with and without cachexia), so as to provide evidence for the clinical prevention and treatment of CRC.

Materials and methods

Patients and groups

Patients with CRC who underwent surgery in the Department of General Surgery from January 2020 to December 2020 and patients who underwent colonoscopy in Endoscopic Center during this period were selected in Zhongshan Hospital, Fudan University. Inclusion criteria: (1) patients with CRC were pathologically diagnosed as colorectal adenocarcinoma; (2) patients with colorectal polyp were detected by colonoscopy and pathologically confirmed as adenomas; (3) healthy controls were confirmed by colonoscopy and no polyp was found; (4) patients performed abdominal CT scans within 30 days before surgery or colonoscopy. The diagnostic criteria of cancer cachexia referred to the international consensus on cancer cachexia proposed in 2011 as weight loss of more than 5% in the past 6 months [25]. In this study, all patients were divided into 4 groups: healthy controls (patients without colorectal polyp), polyp group (patients with colorectal polyp), cancer group (CRC patients without cachexia), and cachexia group (CRC patients with cachexia). The patient’s age and gender were recorded in all 4 groups of patients. Cancer stages were recorded based on the American Joint Committee on Cancer stage (8th edition) groupings in CRC groups with and without cachexia. The ethics committee of Zhongshan Hospital, Fudan University approved this study.

Adipose tissue and muscle areas determination of abdominal CT

Abdominal CT scans were performed within 30 days before colonoscopy or surgery. CT parameters for each patient were as follows: contrast-enhanced or unenhanced, 120 kVp, and 290 mA. The scanning layer was 1–5 mm thick and ranged from the xiphoid process to pubic symphysis. The areas of SAT, VAT, SM, as well as IMAT, were segmented by previously described method by our team [15]. A representative CT image marked with different parts of adipose tissue and SM was shown in Fig. S1.

Statistical analyses

Categorical variables were described as a number with percentages and were compared using χ2 test. Continuous variables were described as mean with standard deviation and were compared using one-way ANOVA and linear regression. A Bonferroni correction was applied to adjust for multiple comparisons in one-way ANOVA. Univariate and multivariate linear regression were both adopted to evaluate the crude and adjusted difference among different disease statuses. Two-sided tests were used, and a P-value < 0.05 was considered statistically significant. All statistical analyses were carried out with Stata 14.0.

Results

Characteristics of enrolled patients

In this study, we included 483, 503, 399, and 128 patients in the healthy controls, polyp group, cancer group, and cachexia group, respectively. Table 1 showed the characteristics of age, gender, and abdominal fat and muscle composition of patients in each group. Significant differences were detected in age, gender and abdominal fat and muscle composition among the 4 groups (P < 0.05). The overall distributions of the abdominal fat and muscle composition in different genders were shown in Fig. 1.
Table 1
Patients’ characteristics of four groups
 
Healthy
(n = 483)
Poloyp
(n = 503)
Cancer
(n = 399)
Cachexia
(n = 128)
P
Age
60.67 ± 11.62
62.82 ± 10.59
63.03 ± 10.53
63.29 ± 11.11
0.002
Male (%)
181(37.47)
267(53.08)
259(65.24)
67(54.03)
< 0.001
SM
115.87 ± 27.64
122.90 ± 30.00
125.21 ± 30.41
110.64 ± 25.81
< 0.001
IMAT
11.31 ± 6.58
11.44 ± 6.60
10.39 ± 5.62
9.38 ± 6.42
0.006
VAT
113.52 ± 64.95
133.61 ± 67.00
129.15 ± 69.23
90.80 ± 61.21
< 0.001
SAT
138.50 ± 53.40
138.68 ± 55.29
126.93 ± 54.84
103.96 ± 55.66
< 0.001
Note: SAT: subcutaneous adipose tissue, VAT: visceral adipose tissue. IMAT: intramuscular adipose tissue; SM: skeletal muscle

Changes of abdominal fat and muscle composition from normal mucosa to polyp and cancer

Firstly, we compared the change of abdominal fat and muscle composition in the process of CRC from normal mucosa to polyp and cancer. Due to the obvious difference in abdominal fat and muscle composition between different genders, we compared the changes of each index according to different gender separately. As shown in Fig. 2, we found that there was no significant difference between the SM area and IMAT area among the healthy controls, polyp group, and cancer group in both genders. However, the VAT area of the polyp group was significantly higher than that of the healthy controls both in male (156.32 ± 69.71 cm2 vs. 141.97 ± 79.40 cm2, P = 0.014) and female patients (108.69 ± 53.95 cm2 vs. 96.28 ± 46.70 cm2, P = 0.044). There was no significant difference in VAT area both between the polyp group and cancer group, and between healthy controls and cancer group. There was no significant difference of SAT area between the polyp group and the healthy controls in male (126.40 ± 43.52 cm2 vs. 120.15 ± 48.47 cm2, P = 0.499) and female patients (152.16 ± 63.23 cm2 vs. 149.62 ± 53.25 cm2, P = 1.000). However, SAT area decreased significantly in the male cancer group compared with the polyp group (111.16 ± 46.98 cm2 vs. 126.40 ± 43.52 cm2, P = 0.001), while no such change was observed in female patients (157.62 ± 56.21 cm2 vs. 152.16 ± 63.24 cm2, P = 1.000). These results indicated that SAT begin to lose in male patients after the occurrence of CRC. The P values of these three groups compared with each other were shown in Table 2.
Table 2
P values of healthy group, polyp group, and cancer group compared with each other by different genders
 
SM
IMAT
SAT
VAT
M
F
M
F
M
F
M
F
P1
1.000
1.000
1.000
1.000
0.499
1.000
0.044
0.014
P2
0.201
0.556
0.498
1.000
0.163
0.641
1.000
1.000
P3
0.065
0.416
0.335
1.000
0.001
1.000
0.180
0.647
Note: P1: polyp group VS. healthy group; P2: cancer group VS. healthy group; P3: cancer group VS. polyp group; SAT: subcutaneous adipose tissue, VAT: visceral adipose tissue. IMAT: intramuscular adipose tissue; SM: skeletal muscle; M: male; F: female

Abdominal fat and muscle composition difference between different stages of CRC and healthy controls

To clarify the abdominal fat and muscle composition characteristics in different stages of CRC, we compared abdominal fat and muscle composition difference between healthy controls and 3 other groups. As shown in Table 3, abdominal fat and muscle composition was compared after adjustment for age and gender. The SM area of the cachexia group was significantly lower than healthy controls, with a mean reduction area of 9.25 cm2 (95% CI: 5.39–13.11 cm2, P < 0.001). There was no significant difference of SM area between polyp group and cancer group compared with the healthy controls. Similarly, we found that IMAT area was significantly lower only in the cachexia group, with a decreased area of 1.93 cm2 (95% CI: 0.54–3.32 cm2, P = 0.006). The SAT area was found slightly higher in the polyp group and lower in the cancer group, and decreased significantly in the cachexia group, with a reduction area of 28.84 cm2 (95% CI: 17.84–39.83 cm2, P < 0.001). Interestingly, we found that the VAT area of the polyp group increased significantly by 12.19 cm2 (95% CI: 4.18–20.20 cm2, P = 0.003) compared to the healthy controls. There was no significant difference of VAT area between the cancer group and the healthy controls, while the VAT area of the cachexia group decreased significantly by 31.31 cm2 (95% CI: 18.12–44.51 cm2, P < 0.001) compared to the healthy controls.
Table 3
Relative changes of abdominal fat and muscle composition in different stages of CRC compared to healthy group
 
SM
IMAT
SAT
VAT
 
Univariate
Multivariate
Univariate
Multivariate
Univariate
Multivariate
Univariate
Multivariate
 
β
P
β
P
β
P
β
P
β
P
β
P
β
P
β
P
Age
-0.73
(-0.86,
-0.59)
< 0.001
-0.74
(-0.83,
-0.65)
< 0.001
0.20
(0.17,
-0.23)
< 0.001
0.20
(0.17,
0.23)
< 0.001
-0.40
(-0.66,
-0.14)
0.003
-0.37
(-0.62,
-0.12)
0.004
0.92
(0.60,
1.23)
< 0.001
0.91
(0.61,
1.21)
< 0.001
Sex
42.77
(40.64,
44.90)
< 0.001
43.15
(41.17,
45.12)
< 0.001
-1.35
(-2.04,
-0.67)
< 0.001
-1.21
(-1.87,
-0.56)
< 0.001
-33.38
(-38.95,
-27.81)
< 0.001
-33.01
(-38.62,
-27.39)
< 0.001
43.16
(36.41,
49.91)
< 0.001
42.63
(35.89,
49.36)
< 0.001
Healthy
0.00
---
0.00
---
0.00
---
0.00
---
0.00
---
0.00
---
0.00
---
0.00
---
Polyp
7.03 (3.35,
10.71)
< 0.001
2.11
(-0.21,
4.44)
0.074
0.14
(-0.67,
0.95)
0.740
-0.08
(-0.85,
0.68)
0.833
0.18
(-6.75,
7.11)
0.959
5.50
(-1.18,
12.17)
0.106
20.09
(11.65,
28.53)
< 0.001
12.19
(4.18,
20.20)
0.003
Cancer
9.33
(5.17,
13,49)
< 0.001
-1.48
(-4.15,
1.19)
0.277
-0.92
(-1.86,
0.02)
0.055
-1.06
(-1.96,
-0.16)
0.021
-11.57
(-19.27,
-3.86)
0.003
-1.29
(-8.83,
6.24)
0.736
15.62
(6.25,
25.00)
0.001
1.26
(-7.78,
10.30)
0.784
Cachexia
-5.23
(-11.39,
0.92)
0.095
-9.25
(-13.11,
-5.39)
< 0.001
-1.93
(-3.32,
-0.54)
0.006
-2.29
(-3.59,
-0.99)
0.001
-34.54
(-46.04,
-23.05)
0.001
-28.84
(-39.83,
-17.84)
< 0.001
-22.72
(-36.71,
-8.73)
0.001
-31.31,
(-44.51,
-18.12)
< 0.001
Note: β(cm2); SAT: subcutaneous adipose tissue, VAT: visceral adipose tissue. IMAT: intramuscular adipose tissue; SM: skeletal muscle; M: male; F: female

Relative changes of abdominal fat and muscle composition in cachexia group compared to other groups

We focused on comparing the changes of abdominal fat and muscle composition in CRC patients with cachexia. By comparing the abdominal fat and muscle composition between the cachexia group and 3 other groups, we found that there were significant differences between the cachexia group and any other groups (Table 4). As shown in Fig. 1, significant difference was detected between cachexia group and other groups, regardless of male and female patients. Most of all, the SAT area of cachexia group deceased 28.84 cm2 (95% CI: 17.84–39.83 cm2, P < 0.001), 34.33 cm2 (95% CI: 23.38–45.27 cm2, P < 0.001), and 27.54 cm2 (95% CI: 16.11–38.98 cm2, P < 0.001), compared with the healthy controls, polyp group, and cancer group, respectively. The VAT area of cachexia group deceased 31.31 cm2 (95% CI: 18.12–44.51 cm2, P < 0.001), 43.51 cm2 (95% CI: 30.36–56.65 cm2, P < 0.001) and 32.57 cm2 (95% CI: 18.85–46.29 cm2, P < 0.001), compared with the healthy controls, polyp group, and cancer group, respectively. A higher extent of loss in VAT was observed in the cachexia group compared with SAT, suggesting that VAT was more metabolically active than SAT in CRC patients with cachexia.
Table 4
Relative changes of abdominal fat and muscle composition in CRC patients with cachexia compared to other groups
 
SM
IMAT
SAT
VAT
 
Univariate
Multivariate
Univariate
Multivariate
Univariate
Multivariate
Univariate
Multivariate
 
β
P
β
P
β
P
β
P
β
P
β
P
β
P
β
P
Age
-0.73
(-0.86,
-0.59)
< 0.001
-0.74
(-0.83,
-0.65)
< 0.001
0.20
(0.17,
-0.23)
< 0.001
0.20
(0.17,
0.23)
< 0.001
-0.40
(-0.66,
-0.14)
0.003
-0.37
(-0.62,
-0.12)
0.004
0.92
(0.60,
1.23)
< 0.001
0.91
(0.61,
1.21)
< 0.001
Sex
42.77
(40.64,
44.90)
< 0.001
43.15
(41.17,
45.12)
< 0.001
-1.35
(-2.04,
-0.67)
< 0.001
-1.21
(-1.87,
-0.56)
< 0.001
-33.38
(-38.95,
-27.81)
< 0.001
-33.01
(-38.62,
-27.39)
< 0.001
43.16
(36.41,
49.91)
< 0.001
42.63
(35.89, 49.36)
< 0.001
Healthy
5.23
(-0.92,
11.39)
0.095
9.25
(5.39,
13.11)
< 0.001
1.93
(0.54,
3.32)
0.006
2.29
(0.99,
3.59)
0.001
34.54
(23.05,
46.04)
< 0.001
28.84
(17.84,
39.83)
< 0.001
22.72
(8.73,
36.71)
0.001
31.31
(18.12,
44.51)
< 0.001
Polyp
12.24
(6.10,
18.41)
< 0.001
11.36
(7.52,
15.21)
< 0.001
2.07
(0.68,
3.46)
0.004
2.21
(0.91,
3.50)
0.001
34.72
(23.23,
46.22)
< 0.001
34.33
(23.38,
45.27)
< 0.001
42.81
(28.82,
56.80)
< 0.001
43.51
(30.36,
56.65)
< 0.001
Cancer
14.57
(8.12,
21,09)
< 0.001
7.76
(3.72,
11.80)
< 0.001
1.01
(-0.46,
2.48)
0.180
1.22
(-0.15,
2.60)
0.080
22.97
(11.00,
34.95)
< 0.001
27.54
(16.11,
38.98)
< 0.001
38.35
(23.77,
52.92)
< 0.001
32.57
(18.85,
46.29)
< 0.001
Cachexia
0.00
---
0.00
---
0.00
---
0.00
---
0.00
---
0.00
---
0.00
---
0.00
---
Note: β(cm2); SAT: subcutaneous adipose tissue, VAT: visceral adipose tissue. IMAT: intramuscular adipose tissue; SM: skeletal muscle; M: male; F: female

Discussion

In this study, by comparing the abdominal fat and muscle composition in patients with and without colorectal polyp, CRC patients with and without cachexia, we found significant differences of abdominal fat and muscle composition in different stages of CRC. Most importantly, VAT area was the largest in patients with colorectal polyp compared to other groups. In CRC patients with cachexia, the areas of SAT, VAT, SM, as well as IMAT were all found decreased significantly compared to other groups. This is the first comprehensive study focused on the of abdominal fat and muscle composition difference during the different stages of CRC progression from normal mucosa to polyp to cancer and cachexia.
Although the association between VAT and CRC was controversial, its association with colorectal polyp was quite well established [31, 32]. Various studies have demonstrated that increase in VAT area was an independent risk factor for colorectal polyp [33]. In this study, significant increase of VAT area was found in the patients with polyp compared with the healthy controls both in male and in female. Further research showed that the increase of VAT in female was higher than that in male, suggesting that the increase of VAT was more likely to promote the occurrence of adenoma in female patients. No significant increase of SAT area was observed in patients with polyp in both genders, which was consistent with the previous study [34]. These results suggested that the growth of VAT but not SAT was a risk factor for colorectal polyp, and female patients should pay more attention to visceral obesity.
VAT related inflammation was supposed to promote CRC initiation and progression [10]. However, Akay et al. reported that areas of VAT and SAT decreased in CRC patients compared with the healthy controls [35]. In this study, we found that the VAT area in CRC patients without cachexia was slightly higher than that of healthy controls, while slightly lower than that of patients with colorectal polyp. This suggested that the VAT was the largest area in patients with colorectal polyp, and VAT began to decrease when cancer occurs. We also found that the SAT area in CRC patient without cachexia was significantly lower than patients with polyp in male, while slightly higher than patients with polyp in female. These results suggests that SAT and VAT may have different roles during the development of CRC.
According to the consensus of cancer cachexia proposed in 2011, patients with cancer cachexia were characterized by muscle loss with or without adipose tissue loss [25]. However, a large number of studies have found that most of cancer patients with cachexia such as gastric cancer and pancreatic cancer were associated with adipose tissue loss [36]. As commonly known, obese patients are more likely to suffer from CRC. When cancer cachexia develops, it is unclear whether adipose tissue will also be significantly decreased on the basis of obesity. In this study, we found both areas of SAT and VAT in patients with cachexia were significantly lower than those of normal patents, polyp patients, and non-cachexia patients. This suggested adipose tissue loss was one of the important characteristics of CRC patients with cachexia.
Ebadi et al. reported that loss of VAT precedes SAT in advanced colorectal and cholangiocarcinoma cancer patients [37]. However, SAT, but not VAT, began to lose in male patients without cachexia in this study, while the loss degree of VAT is greater than that of SAT. Although the underlying mechanism is still not very clear, VAT contains more immune cells than SAT, which may promote lipolysis [8]. More attention should be paid to the SAT loss in the early stage of CRC and VAT loss in the late stage of CRC.
As one of the most important characteristics of cancer cachexia, the study of SM atrophy and its mechanism was more comprehensive than that of adipose tissue loss [38]. In this study, we compared the difference of SM area in different stages of CRC. There was no significant change of SM area among the healthy controls, polyp group, and cancer group, suggesting that SM atrophy did not exist until the early stage of CRC. SM area began to decrease in patient with cachexia, demonstrating that adipose tissue loss precedes muscle loss in CRC patient. It was also suggested that cancer cachexia might be caused by the interaction of muscle and adipose tissue [39].
To our knowledge, this is the first analysis to investigate the IMAT area in different stages of CRC. Interestingly, we found that the IMAT area was smaller in cachexia patients than that in healthy controls and polyp patient, while was similar with CRC patient without cachexia. Nevertheless, as IMAT is a novel topic in adipose tissue depot, more data is needed to validate our findings.
Our study has several limitations. First, this is a retrospective cross-sectional study and has a relatively small cachexia sample size. Second, IMAT area varies greatly among different groups, the final difference in different groups still need to be determined by further research. Thirdly, this study mainly includes two major confounding factors: age and gender. It is unclear whether there are other factors that affect the results. Despite these limitations, we still believe that subcutaneous and visceral adipose tissue play different roles in the different stages of CRC development.

Conclusion

Our research provides important insights into the abdominal fat and muscle composition, especially subcutaneous and visceral adipose tissue, in different stages of colorectal cancer. These findings provide a novel understanding of the association between adipose tissues and CRC. Further studies are essential to understand how different part of adipose tissues, such as SAT, VAT and IMAT, affect CRC progression.

Acknowledgements

We express our gratitude to all patients who participated in the study.

Declarations

All procedures performed in this study involving human participants were in accordance with the ethical standards of the national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Ethics Committee of Zhongshan Hospital, Fudan University (Shanghai, China) approved the review of the medical records (approval number: B2019-193R). Since this is a retrospective statistical analysis based on electronic health records collected as part of standard healthcare, without disclosing the patients’ identity, no individual patients were directly contacted for the data. The need of consent was waived by the institutional ethical committee of Zhongshan Hospital, Fudan University.
Not applicable.

Competing Interest

The authors declare that they have no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Anhänge

Electronic supplementary material

Below is the link to the electronic supplementary material.
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed
2.
Zurück zum Zitat Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRefPubMed Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRefPubMed
3.
Zurück zum Zitat Greuter MJ, Demirel E, Lew JB, Berkhof J, Xu XM, Canfell K, et al. Long-term impact of the dutch Colorectal Cancer Screening Program on Cancer incidence and mortality-model-based exploration of the serrated pathway. Cancer Epidemiol Biomarkers Prev. 2016;25:135–44.CrossRefPubMed Greuter MJ, Demirel E, Lew JB, Berkhof J, Xu XM, Canfell K, et al. Long-term impact of the dutch Colorectal Cancer Screening Program on Cancer incidence and mortality-model-based exploration of the serrated pathway. Cancer Epidemiol Biomarkers Prev. 2016;25:135–44.CrossRefPubMed
4.
6.
Zurück zum Zitat Nagata N, Sakamoto K, Arai T, Niikura R, Shimbo T, Shinozaki M, et al. Visceral abdominal fat measured by computed tomography is associated with an increased risk of colorectal adenoma. Int J Cancer. 2014;135:2273–81.CrossRefPubMed Nagata N, Sakamoto K, Arai T, Niikura R, Shimbo T, Shinozaki M, et al. Visceral abdominal fat measured by computed tomography is associated with an increased risk of colorectal adenoma. Int J Cancer. 2014;135:2273–81.CrossRefPubMed
7.
Zurück zum Zitat Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11:11–8.CrossRefPubMed Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11:11–8.CrossRefPubMed
8.
Zurück zum Zitat Vijay J, Gauthier MF, Biswell RL, Louiselle DA, Johnston JJ, Cheung WA, et al. Single-cell analysis of human adipose tissue identifies depot and disease specific cell types. Nat Metab. 2020;2:97–109.CrossRefPubMed Vijay J, Gauthier MF, Biswell RL, Louiselle DA, Johnston JJ, Cheung WA, et al. Single-cell analysis of human adipose tissue identifies depot and disease specific cell types. Nat Metab. 2020;2:97–109.CrossRefPubMed
10.
Zurück zum Zitat Vazzana N, Riondino S, Toto V, Guadagni F, Roselli M, Davi G, et al. Obesity-driven inflammation and colorectal cancer. Curr Med Chem. 2012;19:5837–53.CrossRefPubMed Vazzana N, Riondino S, Toto V, Guadagni F, Roselli M, Davi G, et al. Obesity-driven inflammation and colorectal cancer. Curr Med Chem. 2012;19:5837–53.CrossRefPubMed
11.
Zurück zum Zitat Greco F, Mallio CA, Grippo R, Messina L, Vallese S, Rabitti C, et al. Increased visceral adipose tissue in male patients with non-clear cell renal cell carcinoma. Radiol Med. 2020;125:538–43.CrossRefPubMed Greco F, Mallio CA, Grippo R, Messina L, Vallese S, Rabitti C, et al. Increased visceral adipose tissue in male patients with non-clear cell renal cell carcinoma. Radiol Med. 2020;125:538–43.CrossRefPubMed
12.
Zurück zum Zitat Im JP, Kim D, Chung SJ, Jin EH, Han YM, Park MJ, et al. Visceral obesity as a risk factor for colorectal adenoma occurrence in surveillance colonoscopy. Gastrointest Endosc. 2018;88:119–127e114.CrossRefPubMed Im JP, Kim D, Chung SJ, Jin EH, Han YM, Park MJ, et al. Visceral obesity as a risk factor for colorectal adenoma occurrence in surveillance colonoscopy. Gastrointest Endosc. 2018;88:119–127e114.CrossRefPubMed
13.
Zurück zum Zitat Gomez-Perez SL, Chaudhry V, Mar W, Patel B, Fantuzzi G, Freels S, et al. Impact of abdominal adipose depots and race on risk for Colorectal Cancer: a case-control study. Nutr Cancer. 2017;69:573–9.CrossRefPubMedPubMedCentral Gomez-Perez SL, Chaudhry V, Mar W, Patel B, Fantuzzi G, Freels S, et al. Impact of abdominal adipose depots and race on risk for Colorectal Cancer: a case-control study. Nutr Cancer. 2017;69:573–9.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat von Hessen L, Roumet M, Maurer MH, Lange N, Reeves H, Dufour JF, et al. High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma. Liver Int. 2021;41:828–36.CrossRef von Hessen L, Roumet M, Maurer MH, Lange N, Reeves H, Dufour JF, et al. High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma. Liver Int. 2021;41:828–36.CrossRef
15.
Zurück zum Zitat Han J, Tang M, Lu C, Shen L, She J, Wu G. Subcutaneous, but not visceral, adipose tissue as a marker for prognosis in gastric cancer patients with cachexia. Clin Nutr. 2021;40:5156–61.CrossRefPubMed Han J, Tang M, Lu C, Shen L, She J, Wu G. Subcutaneous, but not visceral, adipose tissue as a marker for prognosis in gastric cancer patients with cachexia. Clin Nutr. 2021;40:5156–61.CrossRefPubMed
16.
Zurück zum Zitat Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol (1985) 2000, 89:104–110. Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol (1985) 2000, 89:104–110.
17.
18.
Zurück zum Zitat Yim JE, Heshka S, Albu J, Heymsfield S, Kuznia P, Harris T, et al. Intermuscular adipose tissue rivals visceral adipose tissue in independent associations with cardiovascular risk. Int J Obes (Lond). 2007;31:1400–5.CrossRefPubMed Yim JE, Heshka S, Albu J, Heymsfield S, Kuznia P, Harris T, et al. Intermuscular adipose tissue rivals visceral adipose tissue in independent associations with cardiovascular risk. Int J Obes (Lond). 2007;31:1400–5.CrossRefPubMed
19.
Zurück zum Zitat van Vugt JL, Levolger S, Gharbharan A, Koek M, Niessen WJ, Burger JW, et al. A comparative study of software programmes for cross-sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patients. J Cachexia Sarcopenia Muscle. 2017;8:285–97.CrossRefPubMed van Vugt JL, Levolger S, Gharbharan A, Koek M, Niessen WJ, Burger JW, et al. A comparative study of software programmes for cross-sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patients. J Cachexia Sarcopenia Muscle. 2017;8:285–97.CrossRefPubMed
20.
Zurück zum Zitat Yip C, Dinkel C, Mahajan A, Siddique M, Cook GJ, Goh V. Imaging abdominal fat and muscle composition @@@@@@ in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging. 2015;6:489–97.CrossRefPubMedPubMedCentral Yip C, Dinkel C, Mahajan A, Siddique M, Cook GJ, Goh V. Imaging abdominal fat and muscle composition @@@@@@ in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging. 2015;6:489–97.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Faron A, Luetkens JA, Schmeel FC, Kuetting DLR, Thomas D, Sprinkart AM. Quantification of fat and skeletal muscle tissue at abdominal computed tomography: associations between single-slice measurements and total compartment volumes. Abdom Radiol (NY). 2019;44:1907–16.CrossRefPubMed Faron A, Luetkens JA, Schmeel FC, Kuetting DLR, Thomas D, Sprinkart AM. Quantification of fat and skeletal muscle tissue at abdominal computed tomography: associations between single-slice measurements and total compartment volumes. Abdom Radiol (NY). 2019;44:1907–16.CrossRefPubMed
22.
Zurück zum Zitat Murray TE, Williams D, Lee MJ. Osteoporosis, obesity, and sarcopenia on abdominal CT: a review of epidemiology, diagnostic criteria, and management strategies for the reporting radiologist. Abdom Radiol (NY). 2017;42:2376–86.CrossRefPubMed Murray TE, Williams D, Lee MJ. Osteoporosis, obesity, and sarcopenia on abdominal CT: a review of epidemiology, diagnostic criteria, and management strategies for the reporting radiologist. Abdom Radiol (NY). 2017;42:2376–86.CrossRefPubMed
23.
Zurück zum Zitat Chartrand G, Cheng PM, Vorontsov E, Drozdzal M, Turcotte S, Pal CJ, et al. Deep learning: a primer for radiologists. Radiographics. 2017;37:2113–31.CrossRefPubMed Chartrand G, Cheng PM, Vorontsov E, Drozdzal M, Turcotte S, Pal CJ, et al. Deep learning: a primer for radiologists. Radiographics. 2017;37:2113–31.CrossRefPubMed
24.
Zurück zum Zitat Dabiri S, Popuri K, Ma C, Chow V, Feliciano EMC, Caan BJ, et al. Deep learning method for localization and segmentation of abdominal CT. Comput Med Imaging Graph. 2020;85:101776.CrossRefPubMedPubMedCentral Dabiri S, Popuri K, Ma C, Chow V, Feliciano EMC, Caan BJ, et al. Deep learning method for localization and segmentation of abdominal CT. Comput Med Imaging Graph. 2020;85:101776.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.CrossRefPubMed Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.CrossRefPubMed
26.
Zurück zum Zitat Zhang S, Tan S, Jiang Y, Xi Q, Meng Q, Zhuang Q, et al. Sarcopenia as a predictor of poor surgical and oncologic outcomes after abdominal surgery for digestive tract cancer: a prospective cohort study. Clin Nutr. 2019;38:2881–8.CrossRefPubMed Zhang S, Tan S, Jiang Y, Xi Q, Meng Q, Zhuang Q, et al. Sarcopenia as a predictor of poor surgical and oncologic outcomes after abdominal surgery for digestive tract cancer: a prospective cohort study. Clin Nutr. 2019;38:2881–8.CrossRefPubMed
27.
Zurück zum Zitat Fukushima H, Takemura K, Suzuki H, Koga F. Impact of Sarcopenia as a Prognostic Biomarker of Bladder Cancer.Int J Mol Sci2018,19. Fukushima H, Takemura K, Suzuki H, Koga F. Impact of Sarcopenia as a Prognostic Biomarker of Bladder Cancer.Int J Mol Sci2018,19.
28.
Zurück zum Zitat Ryan AM, Sullivan ES. Impact of musculoskeletal degradation on cancer outcomes and strategies for management in clinical practice. Proc Nutr Soc. 2021;80:73–91.CrossRefPubMed Ryan AM, Sullivan ES. Impact of musculoskeletal degradation on cancer outcomes and strategies for management in clinical practice. Proc Nutr Soc. 2021;80:73–91.CrossRefPubMed
29.
Zurück zum Zitat Kobayashi T, Kawai H, Nakano O, Abe S, Kamimura H, Sakamaki A, et al. Prognostic value of subcutaneous adipose tissue volume in hepatocellular carcinoma treated with transcatheter intra-arterial therapy. Cancer Manag Res. 2018;10:2231–9.CrossRefPubMedPubMedCentral Kobayashi T, Kawai H, Nakano O, Abe S, Kamimura H, Sakamaki A, et al. Prognostic value of subcutaneous adipose tissue volume in hepatocellular carcinoma treated with transcatheter intra-arterial therapy. Cancer Manag Res. 2018;10:2231–9.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Pai PC, Chuang CC, Chuang WC, Tsang NM, Tseng CK, Chen KH, et al. Pretreatment subcutaneous adipose tissue predicts the outcomes of patients with head and neck cancer receiving definitive radiation and chemoradiation in Taiwan. Cancer Med. 2018;7:1630–41.CrossRefPubMedPubMedCentral Pai PC, Chuang CC, Chuang WC, Tsang NM, Tseng CK, Chen KH, et al. Pretreatment subcutaneous adipose tissue predicts the outcomes of patients with head and neck cancer receiving definitive radiation and chemoradiation in Taiwan. Cancer Med. 2018;7:1630–41.CrossRefPubMedPubMedCentral
31.
32.
Zurück zum Zitat Moon JM, Im JP, Kim D, Han YM, Soh H, Song JH, et al. Increasing changes in visceral adiposity is associated with higher risk for colorectal adenoma: multilevel analysis in a prospective cohort. J Gastroenterol Hepatol. 2021;36:1836–42.CrossRefPubMed Moon JM, Im JP, Kim D, Han YM, Soh H, Song JH, et al. Increasing changes in visceral adiposity is associated with higher risk for colorectal adenoma: multilevel analysis in a prospective cohort. J Gastroenterol Hepatol. 2021;36:1836–42.CrossRefPubMed
33.
Zurück zum Zitat Hu H, Cai Y, Huang J, Zhang J, Deng Y. Visceral adipose tissue and the risk of colorectal adenomas: a meta-analysis of observational studies. Eur J Cancer Prev. 2015;24:462–9.CrossRefPubMed Hu H, Cai Y, Huang J, Zhang J, Deng Y. Visceral adipose tissue and the risk of colorectal adenomas: a meta-analysis of observational studies. Eur J Cancer Prev. 2015;24:462–9.CrossRefPubMed
34.
Zurück zum Zitat Jung IS, Shin CM, Park SJ, Park YS, Yoon H, Jo HJ, et al. Association of visceral adiposity and insulin resistance with colorectal adenoma and colorectal cancer. Intest Res. 2019;17:404–12.CrossRefPubMed Jung IS, Shin CM, Park SJ, Park YS, Yoon H, Jo HJ, et al. Association of visceral adiposity and insulin resistance with colorectal adenoma and colorectal cancer. Intest Res. 2019;17:404–12.CrossRefPubMed
35.
Zurück zum Zitat Akay S, Urkan M, Balyemez U, Ersen M, Tasar M. Is visceral obesity associated with colorectal cancer? The first volumetric study using all CT slices. Diagn Interv Radiol. 2019;25:338–45.CrossRefPubMedPubMedCentral Akay S, Urkan M, Balyemez U, Ersen M, Tasar M. Is visceral obesity associated with colorectal cancer? The first volumetric study using all CT slices. Diagn Interv Radiol. 2019;25:338–45.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Ebadi M, Baracos VE, Bathe OF, Robinson LE, Mazurak VC. Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with n-6 fatty acid content. Clin Nutr. 2016;35:1347–53.CrossRefPubMed Ebadi M, Baracos VE, Bathe OF, Robinson LE, Mazurak VC. Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with n-6 fatty acid content. Clin Nutr. 2016;35:1347–53.CrossRefPubMed
38.
Zurück zum Zitat Dolly A, Dumas JF, Servais S. Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know? J Cachexia Sarcopenia Muscle. 2020;11:1413–28.CrossRefPubMedPubMedCentral Dolly A, Dumas JF, Servais S. Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know? J Cachexia Sarcopenia Muscle. 2020;11:1413–28.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Schmidt SF, Rohm M, Herzig S, Berriel Diaz M. Cancer Cachexia: more than skeletal muscle wasting. Trends Cancer. 2018;4:849–60.CrossRefPubMed Schmidt SF, Rohm M, Herzig S, Berriel Diaz M. Cancer Cachexia: more than skeletal muscle wasting. Trends Cancer. 2018;4:849–60.CrossRefPubMed
Metadaten
Titel
Abdominal fat and muscle distributions in different stages of colorectal cancer
verfasst von
Jun Han
Xinyang Liu
Min Tang
Fan Yang
Zuoyou Ding
Guohao Wu
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2023
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10736-2

Weitere Artikel der Ausgabe 1/2023

BMC Cancer 1/2023 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.